After investigating the mechanism of resistance of pancreatic cancer to imatinib treatment, Takayama et al. [83] reported that treatment with 5 μM imatinib failed to suppress pancreatic cancer cell growth, but it is speculated that the MEK–MAPK pathway is responsible for the resistance of pancreatic cancer to imatinib. Here, MAP2K7 is linked to pancreatic neoplasm.